Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A Phase I, Open-label Study to Assess the Pharmacokinetics of Oral Fostamatinib in Healthy Japanese Subjects After Single and Multiple Doses
Age
20–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy male and female (of non-childbearing potential) Japanese subjects
20 to 45 years of age
Body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 45 kg and no more than 100 kg
You may not be if
History or presence of respiratory, GI, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders
Any clinically significant illness, acute infection, known inflammatory process, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product
Smoking in excess of 5 cigarettes per day or equivalent within 30 days of Day 1
Use of prescription or over-the-counter drugs within 2 weeks of first administration of investigational product
